Premium
Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO – TFE 3 gene fusion: report of a unique case expanding the gene fusion spectrum
Author(s) -
Wang Xiaotong,
Xia Qiuyuan,
Ni Hao,
Wang Ziyu,
Ye Shengbing,
Li Rui,
Wang Xuan,
Lv Jinghuan,
Shi Shanshan,
Ma Henghui,
Lu Zhenfeng,
Shen Qin,
Zhou Xiaojun,
Rao Qiu
Publication year - 2016
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12949
Subject(s) - fusion gene , neoplasm , pathology , tfe3 , prostate , cancer research , biology , medicine , gene , cancer , gene expression , genetics , promoter
Recently, an increasing number of TFE 3 rearrangement‐associated tumours have been reported, such as TFE 3 rearrangement‐associated perivascular epithelioid cell tumours ( PEC omas), melanotic Xp11 translocation renal cancers and melanotic Xp11 neoplasms. We have suggested that these tumours belong to a single clinicopathological spectrum. ‘Xp11 neoplasm with melanocytic differentiation’ or ‘melanotic Xp11 neoplasm’ have been proposed to designate this unique neoplasm. Herein, we describe the first case of an Xp11 neoplasm with melanocytic differentiation to be described in the prostate, bearing the novel NONO – TFE 3 gene fusion. This study both adds to the spectrum regarding melanotic Xp11 neoplasms and expands its gene fusion spectrum. Moreover, we discuss the relationship of these rare tumours to neoplasms such as conventional PEC omas, alveolar soft part sarcomas, malignant melanomas, clear cell sarcomas and Xp11 translocation renal cancers.